Evidence against hypercoagulability in coronary artery disease

Author： Gorog P. Ridler C.D. Rees G.M. Kovacs I.B.

Publisher： Elsevier

ISSN： 0049-3848

Source： Thrombosis Research, Vol.79, Iss.4, 1995-08, pp. : 377-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evidence of reduced coronary artery disease risk for apolipoprotein 2/3 heterozygotes

By Mamotte C.D.S. Burke V. Taylor R.R. van Bockxmeer F.M.

European Journal of Internal Medicine, Vol. 13, Iss. 4, 2002-06 ,pp. : 250-255

Elsevier

Access to resources Recommend Favorite

Antihypertensive Drugs and Coronary Artery Disease: Evidence from Controlled Trials

By Verdecchia Paolo Angeli Fabio

High Blood Pressure & Cardiovascular Prevention, Vol. 12, Iss. 3, 2005-01 ,pp. : 119-124

Adis International

Access to resources Recommend Favorite

Endothelin in coronary artery disease

By Pernow John

Scandinavian Cardiovascular Journal, Vol. 38, Iss. 5, 2004-10 ,pp. : 257-258

Informa Healthcare

Access to resources Recommend Favorite

Vectorelectrocardiography in Coronary Artery Disease

By Dellborg Mikael

Scandinavian Cardiovascular Journal, Vol. 35, Iss. 2, 2001-03 ,pp. : 72-74

Informa Healthcare

Access to resources Recommend Favorite

Inflammation and Coronary Artery Disease

Current Vascular Pharmacology, Vol. 1, Iss. 1, 2003-03 ,pp. : 65-70

Bentham Science Publishers

Access to resources Recommend Favorite